medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Hidden heterogeneity and its influence on dengue vaccination impact
Magdalene K. Walters, T. Alex Perkins *
Department of Biological Sciences and Eck Institute for Global Health, University of
Notre Dame, Notre Dame, IN 46556 USA
* Corresponding author: taperkins@nd.edu
ABSTRACT
The CYD-TDV vaccine was recently developed to combat dengue, a mosquito-borne
viral disease that afflicts millions of people each year throughout the tropical and
subtropical world. Its rollout has been complicated by recent findings that vaccinees with
no prior exposure to dengue virus (DENV) experience an elevated risk of severe
disease in response to their first DENV infection subsequent to vaccination. As a result
of these findings, guidelines for use of CYD-TDV now require serological screening prior
to vaccination to establish that an individual does not fall into this high-risk category.
These complications mean that the public health impact of CYD-TDV vaccination is
expected to be higher in areas with higher transmission. One important practical
difficulty with tailoring vaccination policy to local transmission contexts is that DENV
transmission is spatially heterogeneous, even at the scale of neighborhoods or blocks
within a city. This raises the question of whether models based on data that average
over spatial heterogeneity in transmission could fail to capture important aspects of
CYD-TDV impact in spatially heterogeneous populations. We explored this question
with a deterministic model of DENV transmission and CYD-TDV vaccination in a
population comprised of two communities with differing transmission intensities.
Compared to the full model, a version of the model based on the average of the two
communities failed to capture benefits of targeting the intervention to the hightransmission community, which resulted in greater impact in both communities than we
observed under even coverage. In addition, the model based on the average of the two
communities substantially overestimated impact among vaccinated individuals in the
low-transmission community. In the event that the specificity of serological screening is
not high, this result suggests that models that ignore spatial heterogeneity could
overlook the potential for harm to this segment of the population.

1 by peer review and should not be used to guide clinical practice.
NOTE: This preprint reports new research that has not been certified

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

INTRODUCTION
Dengue is a viral, mosquito-borne disease caused by any of four dengue virus (DENV)
serotypes that are transmitted among people by Aedes aegypti and Ae. albopictus
mosquitoes (1). While any of the four DENV serotypes may cause disease, an
individualâ€™s second infection, regardless of DENV serotype, carries an enhanced risk of
causing severe disease (2; 3). This can result in hemorrhagic fever, hospitalization, and,
in some cases, death (1). Due to the widespread distribution of its mosquito vectors (4;
5) dengue has been estimated to pose a risk to a large fraction of the world's
population, both now and in the future (6).
Despite the compelling need for a vaccine against dengue (7), only one dengue
vaccine (CYD-TDV, or Dengvaxia, by Sanofi Pasteur) has been licensed to date. The
rollout of this vaccine has been controversial (8), given that it has been associated with
an elevated risk of severe disease for individuals who experience their first natural
DENV infection at some point after being vaccinated (9). As a result, the Strategic
Advisory Group of Experts on Immunization (SAGE) recommends that CYD-TDV only
be administered to individuals with known prior DENV exposure (10). It is generally
accepted that pre-vaccination serological screening is required to determine whether
individuals meet this criterion (8). As such, we refer to the combination of serological
screening andâ€“in the event of a positive screening resultâ€“vaccination as the
"intervention."
There are three considerations that affect the public health impact of CYD-TDV
vaccination following positive serological screening, each of which depends on baseline
seroprevalence in the population being vaccinated. First, it is essential that screening
have high specificity to avoid harm to seronegative individuals who should not be
vaccinated, particularly in areas with low baseline seroprevalence (11). Second, it is
also important that screening have high sensitivity to ensure that seropositive
individuals benefit from vaccination, particularly in areas with high baseline
seroprevalence (12). Third, an assay for serological screening with a given sensitivity
and specificity is expected to have greater impact in an area with higher baseline
seroprevalence, due to the higher proportion of seropositive individuals and the greater
benefits of herd immunity in these settings (13). For these reasons, baseline
seroprevalence could influence decisions about which screening assay is most
appropriate in a given setting, or whether vaccination with CYD-TDV is appropriate in
the first place.
One major complication to the formulation of policies for CYD-TDV vaccination is
the fact that baseline seroprevalence can vary considerably across space (14). Among
districts within a country, estimates of seroprevalence among nine-year-olds varied from
below 20% to above 80% across departments in Colombia and states in Mexico, due to
subnational variability in environmental drivers of transmission (11). Even below the
level of a city, baseline seroprevalence can vary across neighborhoods or blocks. DENV
seroprevalence ranged 56-77% across neighborhoods of Rio de Janeiro, Brazil (15),
74-91% across neighborhoods of Recife, Brazil (16), 67-90% across neighborhoods in
Iquitos, Peru (17), and 21-100% between adjacent blocks in Maracay, Venezuela (18).
Drivers of variability in DENV seroprevalence at this spatial scale can include a number
of factors associated with socioeconomic differences, such as housing quality, free-

2

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

standing water, open containers, and infrequent waste removal (19; 20; 21; 22).
In the event that the spatial resolution of DENV seroprevalence estimates to
inform CYD-TDV policy is limited to larger administrative scales (11), there is a risk that
such policies may not be well-suited to constituent areas where seroprevalence is
above or below average. Under the assumption of uniform seroprevalence, CYD-TDV
implementation could pose a greater risk of severe disease in areas where
seroprevalence is below average. Conversely, assuming uniform seroprevalence could
lead to underestimates of the benefits from vaccination in areas of higher than average
seroprevalence. Another possibility is that individuals from low-transmission
communities could benefit indirectly from vaccination in high-transmission communities
(23). Yet another complication is that vaccination coverage could vary spatially. In urban
areas of Brazil, vaccination coverage has been found to be both negatively (24) and
positively (25) associated with socioeconomic status, due to differences in access to
vaccination and willingness to vaccinate across socioeconomic strata.
To date, mathematical models of CYD-TDV impact have mostly assumed that
transmission is spatially homogeneous within the population being modeled (26). This
leaves an important gap in understanding the implications of uniform policies for CYDTDV vaccination in areas comprised of communities with unrecognized spatial
heterogeneity in baseline DENV seroprevalence. To explore these implications, we
developed and analyzed a simple two-patch model of DENV transmission based on a
system of ordinary differential equations. Transmission potential and baseline
seroprevalence differed between these hypothetical communities, and routine
vaccination with CYD-TDV following serological screening in nine-year-olds was
simulated over a thirty-year horizon. We examined differences in the proportion of cases
averted among vaccinated and unvaccinated individuals in both communities, including
under differing assumptions about human mobility and uneven vaccination coverage.
METHODS
Model Description
Overview

Our model tracks the transmission dynamics of DENV in two communities indexed by c.
These communities, h and l, are differentiated by their respective high and low
and  . They are coupled by human mobility, with
transmission coefficients,
individuals in susceptible classes assumed to spend a fraction, H, of their time in the
community in which they reside and the rest of their time, 1-H, in the other community.
Our model also included demographic change, as we are interested in modeling
transmission over several decades. This includes a year-specific birth rate, Î¼t, year- and
age-specific death rate, Î´t,a, and progression through age classes 0-80+, indexed by a.
Rather than track all four DENV serotypes explicitly (something very few DENV
transmission models do, (27)), our model stratifies individuals by how many DENV
serotypes, s, they have been infected by. Individuals are further classified with respect
to their status as susceptible, infected, or recovered within each community and age
class, resulting in state variables Sc,a,s, Ic,a,s, and Rc,a,s. Individuals in different s strata
experience different probabilities of symptomatic disease,  . As assumed by other
models examining CYD-TDV impacts on DENV transmission (28), we incremented s by
3

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

one upon vaccination. Upon vaccination, individuals were moved to unique states for
 ,   , and   .
vaccine recipients that were stratified similarly: ,,
,,
,,
Model parameters are summarized in Table 1, and a schematic representation of
the order in which transitions among state variables occur is presented in Fig. 1. Code
for numerically solving the system of ordinary differential equations (ODEs) associated
with this model is available at https://github.com/mwalte10/intraurban_dengue_vaccination_impact. This code made use of the ode45 function with
default settings in the deSolve package (29) in the R programming language (30).
Table 1. Model parameters. The timescale of all rate parameters is per day.
Parameter

Definition

Value

Source

Î¼y

Birth rate in year y

2.8x10-5 - 1.2x10-4

(31)

Î´y,a

Death rate in year y at age a

4.6x10-7 - 1.2x10-3

(31)

0.975, 1

Assumed

H

Proportion of time spent in
community of residence
(travel, no travel)

Î²h

Transmission coefficient
(travel, no travel)

0.253, 0.245

Calibrated

Î²l

Transmission coefficient
(travel, no travel)

0.127, 0.175

Calibrated

â€«Ý’â€¬Ò§à¯–

Average intervention
coverage across
communities h and l

0.5

Assumed

â€«Ý’â€¬à¯–

Intervention coverage in
community c

0-1

Varied

â€«ÝÝŠÝÝâ€¬

Sensitivity of pre-vaccination
screening

0.95

(13)

â€«Ü¿ÝÝŒÝâ€¬

Specificity of pre-vaccination
screening

0.85

(13)

Î³

Rate of recovery from
infection

0.25

(32)

Ïƒ

Rate of loss of crossimmunity

0.0023

(26)

ß©à¯¦

Proportion of DENV
infections that result in
symptomatic disease
(s = 0, 1, 2, 3)

0.53, 1, 0.115, 0.115

(26)

4

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure 1. Schematic representation of transitions (arrows) among state variables
(boxes). Demographic parameters and human mobility are excluded for simplicity.
Demography
Our model tracked ages in one-year increments from zero to 79, and individuals aged
80 or older were binned into a single group. Transitions into ages one to 80+ occurred
at a daily rate of Ga = 365-1. Transitions out of ages zero to 79 occurred at rate  =
365-1, while individuals in the terminal age class of 80+ years remained there until
death. Births occurred at year-specific, daily rate Î¼t per capita, which was multiplied by
total population Nc(t) to obtain the overall rate at which newborns entered community c
through the Sc,0,1 compartment. Deaths occurred at year- and age-specific, daily rate Î´t,a
for individuals in all states. The background death rate, Î´t,a, was assumed to adequately
capture the small proportion of DENV infections that resulted in death. Although our
model was not designed with a specific population in mind, we used birth and death
rates from Brazil (31) given that it is a large, dengue-endemic country that has been the
subject of CYD-TDV modeling before (13; 26). To ground our analysis in contemporary
demographic rates, we assumed that CYD-TDV vaccination began in 2020, meaning
that the model burn-in period began in 1960 and that vaccination impacts were tracked
until 2050. Over the course of this timeframe, birth rate decreased more than four-fold
(Fig. 2A), and child mortality decreased while mortality among older ages increased
(Fig. 2B).

5

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure 2. Demographic inputs over the period of model burn-in (left of vertical
line) and post-vaccination (right of vertical line). A) Birth rate per 1,000 individuals.
B) Death rate per 1,000 individuals, with four ages highlighted that span the diversity of
patterns across ages.
DENV transmission
Like most models of mosquito-borne pathogen transmission (33), we did not explicitly
incorporate mosquitoes into our model. Instead, the contribution of mosquitoes to DENV
V
transmission was implicitly captured by transmission coefficients, Î²h and Î²l. Within each
h
community, we assumed that human-mosquito encounters were well-mixed and
homogeneous, consistent with standard assumptions for ODE models. Between
communities, we assumed that residents of one community spent a proportion, 1-H, of
their time in the other community and were, therefore, subject to the force of DENV
infection in that community during that time. Rather than model DENV serotypes
explicitly, we assumed that the force of DENV infection was proportional to
4-s, or the number of serotypes to which an individual had not yet been exposed.
Individuals progressed through their period of active infection â€“ and infectiousness to
ity
mosquitoes â€“ at rate Î³ before progressing through a period of temporary cross-immunity
at rate Ïƒ.
Dengue pathogenesis
Although the risk of severe disease is typically considered an important consideration
for models of CYD-TDV vaccination impact, we limited our model to two types of
infection: asymptomatic or symptomatic. Symptomatic and severe disease are often
assumed to be highest among secondary infections, second highest among primary
lts
infections, and lowest among post-secondary infections (34). Hence, our model's results
about symptomatic disease may mirror what patterns of severe disease would be, had
we modeled them.

6

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

To parameterize the proportion of infections that result in symptomatic disease
as a function of s,  , we adopted values used in a model by the Hopkins/UF team in
Flasche et al. (2016) (Table 1). We also adopted their assumption that symptomatic
infections are twice as infectious to mosquitoes as asymptomatic infections, despite
substantial uncertainty around that multiplier (35). We chose to adopt values from this
model due to its similarity to our model's structure and its general consistency with
seven other models of CYD-TDV vaccination impact (26).
CYD-TDV vaccination
In this analysis, we examined impacts of routine vaccination of nine-year-olds following
a positive result from serological screening. For those in the Sc,9,0 state, vaccination
occurred at rate vc (1 â€“ spec). For those in the Sc,9,1+, Ic,9,1+, or Rc,9,1+ states, vaccination
occurred at rate vc sens. Vaccinated individuals from the Sc,9,s, Ic,9,s, and Rc,9,s states

then moved to state ,,
. Then, they experienced a period of temporary crossimmunity to other DENV serotypes until they transitioned at rate Ïƒ to the appropriate

,,
or Sc,a,s+1 state.
Given our assumption that vaccination acts as a silent natural infection, there
was no need for a parameter to describe protection afforded by vaccination, other than
through the changes that result in rates of dengue pathogenesis as a consequence of s
being incremented. For serological screening prior to vaccination, we assumed a test
with sensitivity of 0.95 and specificity of 0.85 given the widely held view that both
sensitivity and specificity would need to be high for CYD-TDV to have a positive impact
(36). We held intervention coverage across the population as a whole at 50%, with that
number reflecting a weighted average across two equally sized communities that each
had intervention coverage ranging 0-100% across a range of scenarios that we
considered. To explore the possible influence of a known trade-off between sensitivity
and specificity in current DENV screening tests (37), we carried out additional analyses
in which we varied specificity from 0 to 1 to identify the minimum value necessary to
maintain positive benefits of the intervention.
Model equations
The aforementioned assumptions yielded the following equations that define the ODE
model. Equations are presented in reference to community c, with the other community
denoted as câ€™.
First, the dynamics of susceptible individuals of age a in community c followed
 ,,

  1   ,,

4
 ,,








2     1      1  




  ,  ,,    ,,    ,,  ,  ,, ,



    1    




1

where the first term describes transmission from both communities weighted by the
proportion of time H spent in each by a resident of c. Because individuals in this
compartment have been exposed to s serotypes previously, the rate of infection of
individuals in this class is reduced proportional to s. This formulation makes the
simplifying assumption that there is equal circulation of the four DENV serotypes at any
given time. Also within this first term of eqn. (1), contributions of infectious individuals
7

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

are doubled for the proportion ß©à¯¦ who are symptomatic. The second term in eqn. (1)
indicates that vaccination occurs at rate , , which is equal to (1 - spec)  for s = 0 and
sens  for s > 0. In the third and fourth terms of eqn. (1), individuals age in ( ) and
age out ( ) of each age class at a daily rate. In the fifth term of eqn. (1), deaths occur
at the age- and time-specific rate , . For s = 0,  is added to the susceptible state to
represent births into the first susceptible class. In the sixth term of eqn. (1), individuals
from the previous recovered class lose cross-protective immunity and enter the
susceptible pool at rate , but only for s > 1.
Second, the dynamics of infected individuals of age a in community c followed


 ,,

 1   ,,

4





 2     1      1  






    1     


  ,,    ,,  ,  ,,   ,, .



2

The first term in eqn. (2) is equal to the negative of the first term in eqn. (1), because
they both describe the same transition. Similarly, the second, third, and fourth terms of
eqn. (2) describe aging in and out of ,, and dying while being in that state. The fifth
term of eqn. (2) describes individuals who recover from infection at rate .
Third, the dynamics of recovered individuals of age a in community c followed
,,

  ,,  ,,   , 
â€“

,,

  

,,

   ,,  ,  ,, .

3

The only term in eqn. (3) that did not appear in eqns. (1) or (2) is the second term,
which describes loss of cross-protective immunity at rate .
Fourth, when individuals in ,, or ,, become vaccinated, they transition to
 , the dynamics of which follow
state ,,
,,

  ,  ,,

  , 

,,

  ,,   ,,    ,,    ,,  ,  ,, .

4

, entering

Eventually, vaccinated individuals lose cross-protective immunity at rate
 , the dynamics of which follow
state ,,
 ,,

  1   ,,

4
  ,,







 2     1      1  






   ,,    ,,  ,  ,, .



    1    


5


The dynamics of ,,
in eqn. (5) are similar to those of ,, in eqn. (1) except that

there is no input to ,,
due to vaccination, and the force of infection has been reduced
due to s effectively being incremented by 1 following vaccination. Individuals in state

 , the dynamics of which follow
,,
who become infected transition to state ,,

8

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

 ,,

 1   ,,

4








2     1      1  




    1    


  ,,    ,,    ,,  ,  ,, .





6


in eqn. (6) are effectively the same as those of ,, in eqn. (2).
The dynamics of ,,

Calibration
Following Flasche et. al (26), we used seroprevalence of nine-year-olds (SP9) as a
proxy for DENV transmission intensity. Transmission coefficients were chosen to
generate an SP9 of 20% in the low-transmission community and an SP9 of 80% in the
high-transmission community. When both communities were evaluated together, this
yielded an SP9 of 50%. This relatively wide range in SP9 was chosen purposefully, so
as to explore the effects of a wide range in transmission intensities within a single,
interconnected community. In particular, we chose a lower value of 20% so that a
community in which CYD-TDV might possibly have a negative impact was considered.
and  that would yield the desired values of SP9 in the
To identify values of
two communities, we solved the system of ODEs for sixty years under 100 different
combinations of transmission coefficients for each community spanning a 10x10 grid of
0-0.2 for  and 0.2-0.3 for . To allow for interpolation between these values, we
estimated the relationships between ,  , and SP9 using thin-plate splines. Values of
and  yielding values of SP9 of 20% and 80%, respectively, under mobility and nomobility scenarios are provided in Table 1. Code for this calibration process is available
at https://github.com/mwalte10/intra-urban_dengue_vaccination_impact/calibration.R.
Analyses
We assessed the impacts of CYD-TDV vaccination by quantifying two metrics,
proportion of cases averted and force of infection, described below. We did so
separately in the two communities under scenarios with and without mobility and across
varying levels of coverage allocated between the communities. We also performed the
same calculations for a single, well-mixed community with SP9 = 0.5, which was
intermediate between that of the low- (0.2) and high-transmission (0.8) communities.
Force of infection
To quantify the effects of the intervention on the overall dynamics of DENV
transmission, we examined force of infection before and after introduction of CYD-TDV.
We calculated force of infection as the rate at which susceptible people became
infected on an annual basis, which corresponded to a weighted average of the first term
in eqns. (2) and (6) across all a and s but stratified by c and c'.
Proportion of cases averted
Following previous work (13; 26), we used the proportion of symptomatic cases averted
to quantify the impacts of CYD-TDV vaccination from a public health perspective.
Negative values indicated an increase in cases, while positive values indicated a
decrease. We applied this metric to vaccinated and unvaccinated populations
separately to allow for the effects of direct and indirect protection to be assessed.
9

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Because there is no corresponding group of vaccinated individuals in the model with no
o
vaccination, we calculated the proportion of symptomatic cases averted by comparing
equivalent fractions of age groups that were subject to vaccination in the model with
vaccination.
RESULTS
Model validation
We compared the proportion of cases averted under our model to that under models
used by Flasche et al. (26) at five baseline seroprevalence levels (10%, 30%, 50%,
70%, and 90%). As a function of baseline seroprevalence, the pattern of cases averted
under our model was qualitatively similar to that under the other models (Fig. 3).
Specifically, our model captured the same overall trend between baseline
e
seroprevalence and cases averted and also predicted a switch from negative to positive
cases averted as baseline seroprevalence increased from 10% to 30% (Fig. 3).
Whereas this version of our model did not involve pre-vaccination screening (to be
comparable to models used at the time by Flasche et al. (26)), the version of our model
used to generate all subsequent results did involve pre-vaccination screening.

Figure 3. Model validation. We compared the proportion of cases averted predicted by
our model to the range of predictions from eight models from Flasche et al. (26) across
a range of values of baseline seroprevalence.
Model behavior in the presence of vaccination
In all of our analyses, intervention coverage across the overall population was fixed at
50%, but the allocation of that coverage between the two communities varied.
nd
Vaccination coverage depended on intervention coverage, SP9 within a community, and
10

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

the specificity and sensitivity of pre-vaccination screening. The highest vaccination
coverage was achieved in the high-transmission community when 100% of the
intervention was allocated there (Fig. 4). Under this scenario, 65.6% of the vaccinationeligible population in the high-transmission community was vaccinated. The lowtransmission community generally had much lower vaccination coverage, with a peak of
14.9% coverage when 100% of the intervention was allocated there. In a version of the
h
model with a single community with SP9 = 0.5, vaccination coverage was 21.2%, which
was similar to vaccination coverage in the overall population when the intervention was
allocated evenly across the two communities (Fig. 4).

Figure 4. Dependence of vaccination coverage on intervention coverage.
Vaccination coverage in each community (HT: high-transmission, LT: low-transmission)
and the overall population (colored lines) was a function of intervention coverage in
each community (x-axis), as well as the sensitivity and specificity of serological
e
screening and seroprevalence among nine-year-olds, SP9 (fixed at default values). The
+ symbol indicates vaccination coverage in a single community with SP9 equal to the
average of that of the low- and high-transmission communities.
Vaccination lowered the force of infection (FOI) in both communities, regardless
of our assumptions about mobility (Fig. 5). When we assumed that there was no
se
mobility between the two communities (Fig. 5A), each experienced its greatest decrease
in FOI when it experienced higher intervention coverage. When we assumed that there
was a modest degree of mobility between the two communities (Fig. 5B), both
experienced greater decreases in FOI when intervention coverage was higher in the
high-transmission community. This demonstrates that vaccination in the highg
transmission community indirectly benefits the low-transmission community by reducing
FOI there. Comparing the scenarios with and without mobility, the low-transmission

11

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

community showed greater differences between these two scenarios than did the hightransmission community (Fig. 5), which was a result of transmission dynamics in the
low-transmission community being primarily driven by the high-transmission community
when there was mobility between the two communities. In a version of the model with a
single community with SP9 = 0.5, the proportional reduction in force of infection was
6.0%, which was greater than in the high-transmission community but less than in the
low-transmission community when the intervention was allocated evenly (Fig. 5).

Figure 5. Proportional reduction in force of infection as a function of the
allocation of intervention coverage across low- and high-transmission
communities. Reductions are in reference to a baseline scenario with no intervention
and are presented under scenarios in which the two communities (HT: highh
transmission, LT: low-transmission) were or were not assumed to be connected through
human mobility. The + symbol indicates the proportional reduction in force of infection in
a single community with SP9 equal to the average of that of the low- and hightransmission communities.
Vaccination impact in the absence of mobility
When the two communities were not connected through mobility, each experienced its
greatest benefit from vaccination when it received 100% of the intervention (Fig. 6A).
This mirrored reductions in FOI observed when each community received higher
coverage (Fig. 5A). The population at large, however, experienced its greatest benefit
when nearly 100% of the intervention was allocated to the high-transmission community
(Fig. 6A). This is a result of the fact that the majority of infections occurred in that
community. Because most of the population was unvaccinated, these trends for the
overall population also applied to the unvaccinated population (Fig. 6C).

12

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure 6. Proportion of cases averted under an assumption of no mobility
between the two communities. Results are a presented as a function of the allocation
n
of intervention coverage across the two communities (x-axis) (HT: high-transmission,
LT: low-transmission) and broken down by vaccination status (columns) and community
ity
of residence (color). The + symbol indicates the proportion of cases averted in a single
community with SP9 equal to the average of that of the low- and high-transmission
communities.
Vaccinated individuals in a given community experienced their greatest benefit
when 100% of the intervention was allocated to their home community (Fig. 6B). In the
low-transmission community in particular, this was a consequence of our assumption off
effective pre-vaccination screening, which ensured that the vaccine mostly went to
those who stood to benefit from it (i.e., those for whom s > 0). The vaccinated
individuals in the high-transmission community benefited more than those in the lowtransmission community, because there were more individuals there for whom it was
appropriate to receive CYD-TDV (Fig. 4). The two communities benefited equally when
s
79% of the intervention was allocated to the high-transmission community and 21% was
allocated to the low-transmission community. Under different transmission parameters,
we expect that this same pattern would hold but that the numerical values would differ.
One likely possibility for how the intervention might be deployed in practice is
with even coverage across the two communities. Under this scenario, our model
predicted that 6.6% of cases would be averted in the high-transmission community and
8.5% in the low-transmission community (Fig. 6A). Across the combination of the two
communities, this amounted to an 11.7% reduction in the proportion of cases averted
compared with the optimal scenario in which the intervention was allocated in a 79:21
ratio between the high- and low-transmission communities, respectively (Fig. 6A).
s
Among all individuals, the proportion of cases averted when the intervention was
allocated evenly across the two communities was slightly lower than in a single
community with SP9 = 0.5 (Fig. 6A). This was driven primarily by a higher proportion of
cases averted among unvaccinated individuals in that community (Fig. 6C). In contrast,
the single community with SP9 = 0.5 experienced a lower proportion of cases averted
among vaccinated individuals (Fig. 6B).
13

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Vaccination impact in the presence of mobility
When the two communities were connected through mobility, the high-transmission
community experienced its greatest benefit from vaccination when it received 100% of
the intervention (Fig. 7A). The low-transmission community experienced its greatest
benefit when it received 16% intervention coverage, at the expense of intervention
coverage in the high-transmission community only being 84%. Compared to the
scenario with 0% intervention coverage, increasing intervention coverage to 16% in the
low-transmission community increased the proportion of cases averted there by only
0.2% (Fig. 7A). Because most of the population was unvaccinated, these trends for the
overall population also applied to the unvaccinated population (Fig. 7C).

Figure 7. Proportion of cases averted under an assumption of mobility between
the two communities. Results are a presented as a function of the allocation of
intervention coverage across the two communities (x-axis) (HT: high-transmission, LT:
low-transmission) and broken down by vaccination status (columns) and community of
residence (color). The + symbol indicates the proportion of cases averted in a single
community with SP9 equal to the average of that of the low- and high-transmission
communities.
Vaccinated individuals in a given community experienced their greatest benefit
when 100% of the intervention was allocated to their home community (Fig. 6E). This
benefit amounted to 9.3% of cases averted in the high-transmission community and
2.6% of cases averted in the low-transmission community. Whereas reducing
e
intervention coverage from 100% to 0% in the high-transmission community lowered the
proportion of cases averted among vaccinated individuals there to nearly zero, reducing
g
intervention coverage from 100% to 0% in the low-transmission community resulted in
only a modest reduction in the proportion of cases averted among vaccinated
individuals there (Fig. 7B).
Under the scenario of even intervention coverage across the two communities,

14

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

there were considerably fewer cases averted in both the high- and low-transmission
communities than under the scenario in which 100% of the intervention was allocated to
the high-transmission community (Fig. 7A). Compared to the scenario with 100% of the
intervention allocated to the low-transmission community, the scenario of even
intervention coverage led to considerably more cases averted. Because most of the
cases in the overall population derived from the high-transmission community, relative
impacts of even and uneven intervention coverage scenarios for the overall population
were similar to those for the high-transmission community (Fig. 7A).
Among all individuals, the proportion of cases averted when the intervention was
allocated evenly across the two communities was slightly lower than in a single
community with SP9 = 0.5 (Fig. 7A). This was driven primarily by a higher proportion of
cases averted among unvaccinated individuals in that community (Fig. 7C). In contrast,
the single community with SP9 = 0.5 experienced a lower proportion of cases averted
among vaccinated individuals (Fig. 7B).
Sensitivity analyses
Changes in the distribution of the overall population across the two communities
resulted in modest, readily interpretable changes in our results about vaccination impact
(Fig. 8). First, the proportion of cases averted in the high-transmission community was
largely unaffected by whether more people resided there or in the low-transmission
community (Fig. 8, purple lines across columns). Second, the proportion of cases
averted in the low-transmission community was somewhat more sensitive to changes in
the distribution of the population across the two communities (Fig. 8, yellow lines across
columns), with the optimal intervention coverage in the low-transmission community
being higher when a larger fraction of the overall population resided there. These first
two observations can be explained by the fact that transmission in the low-transmission
community was much more sensitive to the high-transmission community than the
reverse. Third, the proportion of cases averted in the overall population more closely
resembled the proportion of cases averted in whichever community had the larger
population. This was primarily a consequence of how heavily the population-wide
average was weighted by one community or the other.

15

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Figure 8. Sensitivity of the proportion of cases averted to unequal population
sizes across the two communities (columns). Results are a presented as a function
of the allocation of intervention coverage across the two communities (x-axis) (HT: high-transmission, LT: low-transmission) and broken down by vaccination status (rows) and
community of residence (color).
Changes in the specificity of pre-vaccination screening had a substantial
influence on our results about vaccination impact (Fig. 9). Sensitivity of the proportion of
cases averted to screening specificity was greatest among vaccinated individuals, with
extremely low values of specificity resulting in a negative proportion of cases averted in
both low- and high-transmission communities (Fig. 9C & 9D). These effects did differ
somewhat across the two communities though, with the decline in the proportion of
cases averted associated with lower values of specificity being much steeper in the low16

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

transmission community (compare spacing between lines in Fig. 9C & 9D). The
proportion of cases averted among unvaccinated individuals was also sensitive to
screening specificity, but mostly in the low-transmission community (Fig. 9C). This was
a consequence of there being lower seropositivity among potential vaccine recipients in
the low-transmission community, which meant that lower values of screening specificity
had a greater impact on vaccination coverage there than in the high-transmission
community.

Figure 9. Sensitivity of the proportion of cases averted to the specificity of prevaccination screening. Results are a presented as a function of the allocation of
intervention coverage across the two communities (x-axis) (HT: high-transmission, LT:
low-transmission) and broken down by vaccination status (rows) and community of
er
residence (columns). Specificity values range 0-1, with lighter colors representing lower
values and darker colors representing higher values.
17

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

DISCUSSION
Although other models that feature spatial transmission heterogeneity (38; 39; 40; 41)
have been used to project CYD-TDV vaccination impact (26), our study is the first to
directly assess the influence of spatial transmission heterogeneity on projections of
CYD-TDV vaccination impact. To ensure that our model's behavior was comparable to
that of other models, we compared its predictions about vaccination impact to
predictions from eight other models (26) that influenced the WHO's initial policy
recommendation about this vaccine (8), finding comparability between our model and
these others in key respects. Our model's behavior was also sensible in that vaccination
coverage in each community depended on the seropositivity of vaccinees in each (11),
and reductions in force of infection mirrored increases in vaccination coverage. Based
on these results, we deemed our model suitable for making an initial, theoretical
assessment of the impacts of CYD-TDV vaccination in a spatially heterogeneous
population.
In the event that two or more communities are relatively isolated from one
another (e.g., cities within a state), our results based on a model with no mobility
indicate that each community would benefit maximally if 100% of the intervention were
targeted to itself. From the perspective of the overall population (i.e., the state as a
whole rather than each city), targeting the intervention to the community with the highest
transmission would have the greatest impact. In the event that two or more communities
experience an appreciable degree of coupling (e.g., neighborhoods within a city), our
results based on a model with mobility indicate that targeting the intervention to the
community with the highest transmission would have the greatest impact, both from the
perspective of the overall population and from the perspective of each community.
Given that spatial coupling has been found to be important for DENV transmission at
multiple spatial scales (42; 43; 44; 45), taken together, our results suggest that spatial
targeting could enhance the impact of vaccination with CYD-TDV following prevaccination screening. Doing so successfully would require overcoming a number of
challenges to implementation, including more spatially detailed estimates of DENV
seropositivity (22; 46) and more accurate assays for serological screening (47).
Because spatial targeting might not always be feasible, we also considered a
scenario involving even intervention coverage across the two communities. Based on a
model with no mobility, intervention impact under even coverage was only slightly
suboptimal from the perspective of the overall population. Based on a model with
mobility, however, intervention impact under even coverage was considerably less than
under the optimal scenario of targeting the intervention exclusively on the hightransmission community. Moreover, from the perspective of vaccinated individuals, even
intervention coverage across the two communities was always suboptimal, as it reduced
vaccination coverage among seropositive individuals in the high-transmission
community who would have benefited from vaccination (9). At the same time, impact
under even intervention coverage was considerably higher than under scenarios in
which the intervention was allocated preferentially to the low-transmission community.
Due to the possibility that socioeconomic factors could underlie a coupling between
heterogeneities (48) in DENV transmission (19; 20; 21; 22) and access to dengue

18

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

vaccines (24; 25; 49), it will be important for measures to be taken to ensure that
coverage of CYD-TDV following pre-vaccination screening is no less than even, if not
targeted preferentially to communities that contribute disproportionately to transmission.
Projections of CYD-TDV vaccination impact to date have mostly assumed even
coverage in a population in which transmission is spatially homogeneous (12). Agentbased models have been an exception in that they have usually accounted for spatial
heterogeneity to some extent, although they too have neglected the issue of uneven
coverage and have incorporated spatial heterogeneity in ways that are complicated and
highly specific to a given location (38; 39; 40; 41). Comparison of versions of our model
with and without spatial heterogeneity offers simple and straightforward intuition about
whether ignoring spatial heterogeneity might lead to bias in CYD-TDV impact
projections. Overall, our results indicate that models based on a single, spatially
homogeneous population may produce reasonable projections of impact in a spatially
heterogeneous population under even intervention coverage. At the same time, we did
observe tendencies for the model based on a single population to project higher impact
in unvaccinated individuals and lower impact in vaccinated individuals than did the
model based on spatially heterogeneous communities. Most significantly though,
ignoring spatial heterogeneity led to substantial overestimation of impact in vaccinated
individuals in the low-transmission community, which is problematic given safety
concerns about CYD-TDV in seronegative individuals (9; 50). Combined with indications
from our sensitivity analysis that low screening specificity could lead to an increase in
cases among vaccinated individuals in the low-transmission community, this suggests
that there may be scenarios in which models assuming spatial homogeneity predict
positive impacts that are, in reality, negative for a segment of the population.
Although the relatively simple model that we used here is conducive to the
development of intuition about the influence of spatial heterogeneity on CYD-TDV
vaccination impact, it leaves open a number of questions about this issue under more
realistic circumstances. To begin to address these questions, we performed two sets of
sensitivity analyses. The first indicated that a model with uneven population distribution
across high- and low-transmission communities would behave similar to our model with
even population distribution except that the weighting of impact across the two
communities would follow the distribution of population across the two communities.
The second indicated that impact in the low-transmission community was more
sensitive to the specificity of serological screening than was impact in the hightransmission community, although the allocation of intervention coverage across the two
communities also affected the sensitivity of vaccination impact to the specificity of
serological screening. Even so, the generality of our results would best be assessed
through understanding of the extent to which our conclusions hold when analyzed in a
similar fashion by other models in more realistic settings. Similar follow-up analyses
have occurred from the perspective of estimating CYD-TDV cost-effectiveness (51; 52;
53). One way that this could be achieved in practice is if future studies involving models
of CYD-TDV vaccination impact were to perform sensitivity analyses on the issue of
spatial heterogeneity in DENV transmission.
In practice, the spatial scale at which decisions about CYD-TDV vaccination will
be made may be as coarse as a country or the first administrative level within a country
(e.g., state, province) (46). Given that DENV transmission is typified by spatial

19

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

heterogeneity below those scales (15; 16; 17; 18; 22), our results are pertinent to future
modeling projections of the impact of CYD-TDV vaccination policies at those scales.
Although we have shown that projections ignoring spatial heterogeneity may provide
reasonably accurate insights about overall impact under even intervention coverage,
there are other, potentially serious, limitations of those approaches. First, in the event
that there is capacity to target the intervention to high-transmission communities,
models that ignore spatial heterogeneity will underestimate impact. Second, in the event
that socioeconomic drivers or other factors result in unintentional targeting of lowtransmission communities, models that ignore spatial heterogeneity will overestimate
impact. Third, even in the event of even intervention coverage, models that ignore
spatial heterogeneity could substantially overestimate impact, or even overlook the
potential for harm, among vaccinated individuals in low-transmission communities.
Further developments in modeling and additional collection and sharing of fine-scale
spatial data will be important for addressing these issues and maximizing the potential
benefits of this dengue vaccine, and potentially others that come after it (36; 54).
ACKNOWLEDGEMENTS
We thank members of the Perkins Lab for feedback on this work.
REFERENCES
1. Guzman, MG, and E Harris. 2015. Dengue. Lancet 385 9966:453-465.
2. Katzelnick, CL, L Gresh, ME Halloran, JC Mercado, G Kuan, A Gordon, A
Balmaseda, and E Harris. 2017. Antibody-dependent enhancement of severe
dengue disease in humans. Science 358 6365:929-932.
3. Salje, H, DAT Cummings, I Rodriguez-Barraquer, LC Katzelnick, J Lessler, C
Klungthong, B Thaisomboonsuk, et al. 2018. Reconstruction of antibody
dynamics and infection histories to evaluate dengue risk. Nature 557 7707:719723.
4. Kraemer, MUG, ME Sinka, KA Duda, A Mylne, FM Shearer, CM Barker, CG Moore,
et al. 2015. The global distribution of the arbovirus vectors Aedes aegypti and
Ae. albopictus. eLife 4:1-18.
5. Kraemer, MUG, RC Reiner, OJ Brady, JP Messina, M Gilbert, DM Pigott, D Yi, et al.
2019. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes
albopictus. Nature Microbiology 4 5:854-863.
6. Messina, JP, OJ Brady, N Golding, MUG Kraemer, SE Ray, DM Pigott, FM Shearer,
et al. 2019. The current and future global distribution and population at risk of
dengue. Nature Microbiology.
7. DeRoeck, D, J Deen, and JD Clemens. 2003. Policymakersâ€™ views on dengue
fever/dengue haemorrhagic fever and the need for dengue vaccines in four
southeast Asian countries. Vaccine 22:121-129.
8. Wilder-Smith, A, KS Vannice, J Hombach, J Farrar, and T Nolan. 2016. Population
Perspectives and World Health Organization Recommendations for CYD-TDV
Dengue Vaccine. Journal of Infectious Diseases 214:1796-1799.
9. Sridhar, S, M Luedtke, E Langevin, M Zhu, M Bonaparte, T Machabert, S Savarino,
et al. 2018. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
20

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

New England Journal of Medicine 379 4:327-340.
10. World Health Organization. 2018. Revised SAGE Recommendation on Use of
Dengue Vaccine. World Health Organization. April 20. Accessed July 10, 2019.
www.who.int/immunization/diseases/dengue/revised_SAGE_recommendations_
dengue_vaccines_apr2018/en/.
11. RodrÃ­guez-Barraquer, I, H Salje, and DAT Cummings. 2019. Dengue prevaccination screening and positive predictive values. Lancet Infectious Diseases
19 2:132-134.
12. Flasche, S, and PG Smith. 2019. Sensitivity and negative predictive value for a
rapid dengue test. Lancet Infectious Diseases 19 5: 465-466.
13. EspaÃ±a, G, Y Yao, KB Anderson, MC Fitzpatrick, DL Smith, AC Morrison, A WilderSmith, TW Scott, and TA Perkins. 2019. Model-based assessment of public
health impact and cost-effectiveness of dengue vaccination following screening
for prior exposure. PLOS Neglected Tropical Diseases 1-21.
14. Lee, JS, J LourenÃ§o, S Gupta, and A Farlow. 2018. A multi-country study of dengue
vaccination strategies with Dengvaxia and a future vaccine candidate in three
dengue-endemic countries: Vietnam, Thailand, and Colombia. Vaccine 36:23462355.
15. Alves Honorio, N, RM Ribeiro Nogueira, C Torres CodeÃ§o, M SÃ¡ Carvalho, O
GonÃ§alves Cruz, M de Avelar F Mafra MagalhÃ£es, JM GalvÃ£o de AraÃºjo, et al.
2009. Spatial Evaluation and Modeling of Dengue Seroprevalence and Vector
Density in Rio de Janeiro, Brazil. PLOS Neglected Tropical Diseases 3.
16. Braga, C, C Feitosa Luna, CM Martelli, WV de Souza, MT Cordeiro, N Alexander,
MPM de Albuquerquea, JC Silveira JÃºnior, and ET Marques. 2010.
Seroprevalence and risk factors for dengue infection in socio-economically
distinct areas of Recife, Brazil. Acta Tropica 113:234-240.
17. Morrison, AC, SL Minnick, C Rocha, BM Forshey, ST Stoddard, A Getis, DA Focks,
et al. 2010. Epidemiology of Dengue Virus in Iquitos, Peru 1999 to 2005:
Interepidemic and Epidemic Patterns of Transmission. PLOS Neglected Tropical
Diseases.
18. Vincenti-Gonzalez, MF, ME Grillet, ZI Velasco-Salas, EF Lizarazo, MA Amarista,
GM Sierra, C Comach, and A Tami. 2017. Spatial Analysis of Dengue
Seroprevalence and Modeling of Transmission Risk Factors in a Dengue
Hyperendemic City of Venezuela. PLOS Neglected Tropical Diseases 1-21.
19. van Benthem, BH, SO Vanwambeke, N Khantikul, C Burghoorn-Maas, K Panart, L
Oskam, EF Lambin, and P Somboon. 2005. Spatial patterns of and risk factors
for seropositivity for dengue infection. American Journal of Tropical Medicine and
Hygiene 72:201-208.
20. Kikuti, M, GM Cunha, IA Paploski, AM Kasper, MM Silva, AS Tavares, JS Cruz, et
al. 2015. Spatial Distribution of Dengue in a Brazilian Urban Slum Setting: Role
of Socioeconomic Gradient in Disease Risk. PLOS Neglected Tropical Diseases
9:e0003937.
21. Lippi, CA, AM Stewart-Ibarra, AG Munoz, MJ Borbor-Cordova, R Mejia, K Rivero, K
Castillo, WB Cardenas, and SJ Ryan. 2018. The Social and Spatial Ecology of
Dengue Presence and Burden during an Outbreak in Guayaquil, Ecuador, 2012.
International Journal of Environmental Research and Public Health 15:E827.

21

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

22. Salje, H, KK Paul, I Rodriguez-Barraquer, Z Rahman, MS Alam, M Rahman, HM AlAmin, J Heffelfinger, and E Gurley. 2019. Nationally-representative serostudy of
dengue in Bangladesh allows generalizable disease burden estimates. eLife
8:e42869.
23. Shrestha, S, S Chatterjee, KD Rao, and DW Dowdy. 2016. Potential impact of
spatially targeted adult tuberculosis vaccine in Gujarat, India. Journal of the
Royal Society Interface 1-9.
24. Barata, RB, MC Ribeiro, JC Moraes, and B Flannery. 44. Socioeconomic
Inequalities and Vaccination Coverage: Results of an Immunization Coverage
Survey in 27 Brazilian Capitals, 2007â€“08, Brazil. International Journal of
Epidemiology.
25. Branco, F, TM Pereira, BM Delfino, AM BraÃ±a, H Oliart-GuzmÃ¡n, SA Silva
Mantovani, A Camargo Martins, et al. 2014. Socioeconomic inequalities are still a
barrier to full child vaccine coverage in the Brazilian Amazon: a cross-sectional
study in Assis Brasil, Acre, Brazil. International Journal for Equity in Health
13:118-130.
26. Flasche, S, M Jit, I Rodriguez-Barraquer, L Coudeville, M Recker, K Koelle, G Milne,
et al. 2016. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness
of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine
Dengvaxia: A Model Comparison Study. PLOS Medicine.
27. Perkins, TA, RC Reiner, I Rodriguez-Barraquer, DL Smith, TW Scott, and DAT
Cummings. 2014. A review of transmission models of dengue: A quantitative and
qualitative analysis of model features. In Dengue and Dengue Hemorrhagic
Fever, 2nd ed. CAB International.
28. Ferguson, NM, I RodrÃ­guez-Barraquer, I Dorigatti, L Mier-y-Teran-Romero, DJ
Laydon, and DAT Cummings. 2016. Benefits and risks of the Sanofi-Pasteur
dengue vaccine: Modeling optimal deployment. Science 353:1033-1036.
29. Soetaert, K, T Petzoldt, and RW Setzer. 2010. Solving Differential Equations in R:
Package deSolve. Journal of Statistical Software 33:1-25.
30. R Core Team. 2017. R: A Language and Environment for Statistical Computing.
Vienna.
31. United Nations, Department of Economic and Social Affairs, Population Division.
2017. World Population Prospects: The 2017 Revision. Accessed 2019.
32. Meltzer, MI, JG Rigau-PÃ©rez, GG Clark, P Reiter, and DJ Gubler. 1998. Using
disability-adjusted life years to assess the economic impact of dengue in Puerto
Rico: 1984-1994. American Journal of Tropical Medicine and Hygeine 265-271.
33. Reiner, RC, TA Perkins, CM Barker, T Niu, LF Chaves, AM Ellis, DB George, et al.
2013. A systematic review of mathematical models of mosquito-borne pathogen
transmission: 1970â€“ 2010. Journal of the Royal Soceity Interface 1-13.
34. Imai, N, I Dorigatti, S Cauchemez, and NM Ferguson. 2016. Estimating Dengue
Transmission Intensity from Case-Notification Data from Multiple Countries.
PLOS Neglected Tropical Diseases.
35. ten Bosch, QA, HE Clapham, L Lambrechts, V Duoung, P Buchy, BM Althouse, AL
Lloyd, et al. 2018. Contributions from the silent majority dominate dengue virus
transmission. PLOS Pathogens 14:e1006965.
36. Wilder-Smith, A, J Hombach, N Ferguson, M Selgelid, K O'Brien, K Vannice, A

22

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

Barrett, et al. 2019. Deliberations of the Strategic Advisory Group of Experts on
Immunization on the use of CYD-TDV dengue vaccine. Lancet Infectious
Diseases 19:e31-e38.
37. Marrero-Santos, KM, M BeltrÃ¡n, J CarriÃ³n-LebrÃ³n, C Sanchez-Vegas, DH Hamer,
ED Barnett, LM Santiago, and EA Hunsperger. 2013. Optimization of the Cutoff
Value for a Commercial Anti-Dengue Virus IgG Immunoassay. Clinical and
Vaccine Immunology 358-362.
38. Lourenco, J, and M Recker. 2013. Natural, Persistent Oscillations in a Spatial MultiStrain Disease System with Application to Dengue. PLOS Computational Biology
9:e1003308.
39. Perkins, TA, RC Reiner, G Espana, QA ten Bosch, A Verma, KA Liebman, VA PazSoldan, et al. 2019. An agent-based model of dengue virus transmission shows
how uncertainty about breakthrough infections influences vaccination impact
projections. PLOS Computational Biology 15:e1006710.
40. Karl, S, N Halder, JK Kelso, SA Ritchie, and GJ Milne. 2014. A spatial simulation
model for dengue virus infection in urban areas. BMC Infectious Diseases
14:447.
41. Hladish, TJ, CAB Pearson, DL Chao, DP Rojas, GL Recchia, H Gomez-Dantes, ME
Halloran, JRC Pulliam, IM Longini. 2016. Projected impact of dengue vaccination
in Yucutan, Mexico. PLOS Neglected Tropical Diseases 10:e0004661.
42. Stoddard, ST, BM Forshey, AC Morrison, VA Paz-Soldan, GM Vazquez-Prokopec,
H Astete, RC Reiner, et al. 2013. House-to-house human movement drives
dengue virus transmission. Proceedings of the National Academy of Sciences
110:994-999.
43. Wesolowski, A, T Qureshi, MF Boni, PR Sundsoy, MA Johansson, SB Rasheed, K
Engo-Monsen, and CO Buckee. 2015. Impact of human mobility on the
emergence of dengue epidemics in Pakistan. Proceedings of the National
Academy of Sciences 112:11887-11892.
44. Kraemer, MUG, D Bisanzio, RC Reiner, R Zakar, JB Hawkins, CC Freifeld, DL
Smith, SI Hay, JS Brownstein, and TA Perkins. 2018. Inferences about
spatiotemporal variation in dengue virus transmission are sensitive to
assumptions about human mobility: a case study using geolocated tweets from
Lahore, Pakistan. EPJ Data Science 7:16.
45. Kraemer, MUG, TA Perkins, DAT Cummings, R Zakar, SI Hay, DL Smith, and RC
Reiner. 2015. Big city, small world: density, contact rates, and transmission of
dengue across Pakistan. Journal of the Royal Society Interface 12:20150468.
46. Rodriguez-Barraquer, I, H Salje, and DAT Cummings. 2019a. Opportunities for
improved surveillance and control of dengue from age-specific case data. eLife
8:e45474.
47. Wilder-Smith, A, PG Smith, R Luo, C Kelly-Cirino, D Curry, H Larson, A Durbin, et
al. 2019. Pre-vaccination screening strategies for the use of the CYD-TDV
dengue vaccine: A meeting report. Vaccine 37:5137-5146.
48. Vazquez-Prokopec, GM, TA Perkins, LA Waller, AL Lloyd, RC Reiner, TW Scott,
and U Kitron. 2016. Coupled heterogeneities and their impact on parasite
transmission and control. Trends in Parasitology 32:356-367.
49. Godoi, IP, AS Santos, EA Reis, LLP Lemos, CMR Brandao, J Alvares, FA Acurcio,

23

medRxiv preprint doi: https://doi.org/10.1101/19006783; this version posted September 26, 2019. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .

B Godman, and AA Guerra Junior. 2017. Consumer Willingness to Pay for
Dengue Vaccine CYD-TDV, Dengvaxia in Brazil; Implications for Future Pricing
Considerations. Frontiers in Pharmacology 8:41.
50. Rosenbaum, L. 2018. Trolleyology and the Dengue Vaccine Dilemma. New England
Journal of Medicine 379:305-307.
51. Durham, DP, ML Ndeffo Mbah, J Medlock, PM Luz, LA Meyers, AD Paltiel, and AP
Galvani. 2013. Dengue dynamics and vaccine cost-effectiveness in Brazil.
Vaccine 31:3957-3961.
52. Shim, E. 2016. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the
Philippines. American Journal of Tropical Medicine and Hygiene 95:1137-1147.
53. Zeng, W, YA Halasa-Rappel, N Baurin, L Coudeville, and DS Shepard. 2018. Costeffectiveness of dengue vaccination in ten endemic countries. Vaccine 36:413420.
54. Recker, M, K Vannice, J Hombach, M Jit, and CP Simmons. 2016. Assessing
dengue vaccination impact: Model challenges and future directions. Vaccine
34:4461-4465.

24

